Oncology

DREAMM-9 data show belantamab mafodotin in TI NDMM delivers high responses, with longer dosing improving eye safety and quality of life.

Enfortumab vedotin combination delivers lasting complete responses in la/mUC.

ASCO 2026 data show perioperative enfortumab vedotin plus pembrolizumab boosts EFS, OS, and pCR in cisplatin-eligible MIBC.

ASCO 2026: Glofitamab monotherapy shows durable remissions in relapsed mantle cell lymphoma after BTKi, with manageable CRS.

At ASCO 2026, CHRYSALIS-2 data show amivantamab plus lazertinib extends survival in atypical EGFR-mutated NSCLC, reshaping first-line care.

Emerging evidence links GLP-1 receptor agonists to improved breast cancer outcomes and the growing importance of metabolic health in survivorship care.

This interview discusses emerging immunotherapy trends at the 2026 ASCO Annual Meeting, including cancer vaccines, cell-based therapies, ADCs, and AI-driven immune profiling tools poised to reshape oncology care.

Proteomic liquid biopsy technology may improve early breast cancer detection, guide targeted therapy selection, and support longitudinal treatment monitoring in oncology care.

FDA approval brings durvalumab plus BCG to frontline high-risk NMIBC, boosting disease-free survival and expanding oncology options.

Researchers discuss how GLP-1 receptor agonists may be associated with improved survival outcomes in breast cancer and what clinicians should consider as use of these therapies continues to grow.

Phase 3 UTOPIA trial shows UGN-103 intravesical mitomycin after TURBT achieves 78% complete response with favorable safety.

ASCO pooled phase 3 data show that pirtobrutinib in treatment‑naive CLL/SLL delivers 93% responses, durable control, and low cardiac risk.

Erin Zacholski, PharmD, BCOP, discusses the critical role of biomarker testing, immune checkpoint inhibitor selection, and pharmacist-led patient counseling in recurrent and metastatic endometrial cancer management.

Adding immune checkpoint inhibitors to carboplatin and paclitaxel has become the new frontline standard for advanced or recurrent endometrial cancer.

Pharmacy Times speaks with Sarah Sparks, MHA, MBA, Director of Clinical Data Quality at Ontada, through strengthening oncology real-world data quality through clinically relevant edit checks.

The approval is supported by data from the phase 3 TROPION-Breast02 trial.

GLP-1 receptor agonists, molecular profiling, and biomarker-driven treatment strategies may help improve outcomes and personalize care for patients at risk for or diagnosed with endometrial cancer.

Pharmacy Times speaks with Helen Latimer, MPH, to discuss the advancement of HRR genetic testing equity in metastatic prostate cancer.

GLP-1 receptor agonists could influence endometrial cancer prevention, obesity management, fertility preservation, and molecularly guided treatment strategies in gynecologic oncology.

Perioperative durvalumab and tremelimumab plus neoadjuvant enfortumab vedotin improves survival in muscle-invasive bladder cancer.

Researchers at Northwestern University have uncovered a surprising new role for montelukast that could reshape how oncologists approach immunotherapy resistance.

Heavy marijuana smoking may increase lung cancer risk, with cannabis use disorder linked to higher odds of small cell and non–small cell disease.

Pharmacy Times interviews Sarah Spark, MHA, MBA, Director of Clinical Data Quality at Ontada, on how clinically relevant edit checks are improving the accuracy and reliability of real-world oncology data to better support clinical decision-making, research, and patient outcomes.

FACT-accredited centers vs nonaccredited centers may influence CAR T-cell therapy outcomes.

The findings emphasize the growing role of precision oncology and integrated EHR infrastructure in expanding access to targeted therapies.

Emerging evidence surrounding GLP-1 receptor agonists and progestin therapies could influence preventive care strategies and endometrial cancer risk reduction in high-risk patients.

Pharmacy Times interviews Helen Latimer, MPH, about new real-world data examining racial disparities and evolving trends in HRR genetic testing among patients with metastatic prostate cancer and the implications for equitable access to precision oncology care.

The FDA approved 2 new indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer, expanding its use in both neoadjuvant and adjuvant settings.